Digital health expert Dr Jordan Brayanov from Takeda Pharmaceuticals shares his lessons learned delivering virtual trials during Covid-19 and predictions on what’s next for the industry.
Industry experts working at the forefront of drug development, devices and digital health shared their lessons learned delivering virtual trials during the Covid-19 pandemic at Cambridge Cognition’s fourth annual Digital Health Event. Catch up on the key takeways from this thought-leading discussion.
The power of remote assessments is the flexibility in when and where they can be administered. However, with this increased flexibility comes a responsibility to collect data at a frequency that is meaningful but not burdensome for the patient. This article will cover how to navigate this tricky process and strike the balance.
Older adults are consistently under-represented in clinical trials, even though they take more prescription medications than any other group. In this two part series, Dr Kiri Granger will explore this under-presentation and outline practical considerations for including older adults in clinical trials.
Read on for session one: the importance of addressing the evidence-practice gap.
Accurate outcome measures and suitable patient recruitment will be vital to the success of pro-cognitive treatment trials in multiple sclerosis (MS). In this article, we highlight the sensitivity of various CANTAB tasks to cognitive dysfunction in MS, and discuss the advantages of using these computerised assessments over paper-and-pencil based tests. We also consider how CANTAB tasks can be used to screen prospective participants for specific types and severities of cognitive impairment in order to gauge their suitability for inclusion in pro-cognitive intervention trials.
Cambridge Cognition today announced it has won a significant new phase IV clinical trial contract for use of its electronic clinical outcomes assessment (eCOA) platform, CANTAB Connect.
To date, no effective drugs have been developed to address cognitive dysfunction in schizophrenia. Here we will highlight the three main methodological challenges which may be contributing to these high failure rates, and propose potential practical solutions to these problems.
Drug development typically relies upon clinical endpoints established within very controlled laboratory environments. Digital health technologies now provide the opportunity to transition data collection from the clinic into people’s personal lives, thereby providing more accurate conclusions about how a compound can influence their day-to-day life.
High-frequency digital health assessments can not only characterize clinically-relevant data as it occurs in real-time, but capture this information within the patient’s home environment. Therefore, digital health platforms provide an ecologically valid data source which directly maps on to an individual’s daily functioning and real-world outcomes.
Comprehensive neuropsychological testing typically takes hours to complete, which can be mentally and physically burdensome for patients. Furthermore, the travel required and overall time-commitment to undergo these procedures within a clinic can result in decreased study compliance. Together these factors can confound conclusions concerning treatment efficacy. Here we will discuss how digital health can reduce these burdens when implementing therapeutic interventions to improve patient outcomes.
In the first of our digital health series we will outline what the term means, and the opportunities offered, within the context of clinical trials in psychiatry.
The contemporary framework for designing clinical trials is to build a comprehensive cognitive profile of the patient population from thorough but infrequent assessments. However, this framework struggles to capture the daily fluctuations in mood and cognition that many individuals with psychiatric disorders experience. Here we will discuss how the advent of digital health offers the opportunity to capture a more holistic representation of patients’ cognitive function from high-frequency assessments.
Screening patients into early stage Alzheimer’s trials can be costly and time-consuming. Kenton Zavitz, PhD, Director of Clinical Affairs proposes a potential solution for improving recruitment into clinical trials.
We’re pleased to announce that our CANTAB Recruit software is now established in two major Phase III trials into Alzheimer’s disease.
In this post, Director of Clinical Affairs, Dr Kenton Zavitz, looks at the challenge of recruiting the correct patients into Alzheimer's disease trials.
Cambridge Cognition and Boehringer Ingelheim have been investigating cognitive performance among patients with schizophrenia, with a view to improving future pro-cognitive drug trial designs. Our Director of Neuroscience, Dr Kiri Granger, presented the latest findings at ISCTM and SIRS.
The latest FDA draft guidance for clinical trials in early Alzheimer’s disease presents many new opportunities and challenges for drug development.
Dr Kenton Zavitz, Director of Clinical Affairs at Cambridge Cognition, and Dr Robert Smith, Consultant Neuropsychologist, hosted a webinar to discuss clinical trials for early Alzheimer’s disease.
Join them to hear more about overcoming the barriers to expedite the drug development process.
Tuesday 22nd May 2018, 11 a.m. EDT
Can acetylcholinesterase inhibitors and CNS stimulants tackle cognitive dysfunction in multiple scle
Cognitive dysfunction in multiple sclerosis (MS) presents a significant, unmet therapeutic need. Researchers at Cambridge Cognition and the University of Manchester investigated potential solutions to this problem with a systematic review and meta-analysis of pro-cognitive drug trials in MS.
Discussing the methodological considerations, and suggesting recommendations, for successful pro-cognitive drugs trials in schizophrenia.
The importance of recruiting patients for pro-cognitive drug trials in schizophrenia on the basis of cognitive dysfunction.
Introducing a blog-post series to discuss key limitations, and potential improvements, for pro-cognitive drug trials in schizophrenia.
Dr Kiri Granger, Director of Neuroscience, Cambridge Cognition and Dr Steve Brannan, Chief Medical Officer, Karuna Pharmaceuticals Inc. hosted a webinar on how to improve clinical trial success in schizophrenia.
New data demonstrates possibility for speech recognition and online assessments to enhance clinical trials in Alzheimer’s disease.
Enriching participant eligibility for clinical trials through pre-screening for cognitive deficit.
Identifying participants in the ‘pre-clinical’ or ‘prodromal’ stage of Alzheimer's disease prior to the onset of cognitive and functional decline can be challenging, time-consuming and expensive. Can, pre-screening for episodic memory deficits enrich the recruitment of eligible participants in early Alzheimer’s disease clinical trials?
Dr Kiri Granger presented this poster at the International Congress on Schizophrenia Research on the 25th March 2017.